The EGFR exon 20 insertion mutation was also suggested to induce a poor responses to EGFR-TKI [22], and was reported in about 2% of NSCLC or lung adenocarcinoma [23–25], which is similar to our report (2.0%). This evidence concerns the gene EGFR and lung adenocarcinoma.